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Reply by Professor Richard Wise 
The authors pose a number of interesting questions 
which revolve round the observation that, apparently, a 
relatively greater degree of insusceptibility can occur to 
one or more quinolones in comparison with others. 
What is the clinical significance of this observation? 
The increases in the MICs between the two 
isolations of S. pneurnoniae were >%fold for pefloxacin, 
%fold for ofloxacin and ciprofloxacin and 32-fold for 
sparfloxacin. The original isolate must be considered to 
be more resistant to all these agents than the majority 
of strains, as the MIC90 values reported are 8->16 
p g / d  of pefloxacin, 1-2 p g / d  of ofloxacin and 
ciprofloxacin (l), and 0.25-0.5 p g / d  of sparfloxacin 
(2). Hence the questions to answer are: what were the 
mechanisms of resistance in the original isolate and in 
the later isolate, and why was the susceptibility to 
sparfloxacin more affected than that to the other 
quinolones? 
Alterations to DNA gyrase in gram-positive and 
gram-negative bacteria is usually associated with a 4- 
to 32-fold increase in MIC of ciprofloxacin (3) and 
a parallel increase is seen for other quinolones. 
Alterations to the inner membrane in gram-positive 
bacteria can occur. In Staphylococcus aureus the norA 
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gene can alter drug efRux mechanisms, and this can 
differentially affect the various quinolones (3). Indirect 
evidence from our own investigations suggests that 
sparfloxacin has an enhanced capacity to pass certain 
mammalian membranes, and therefore, possibly bacterial 
membranes. Hence the possession of both a norA gene 
and a gyrA mutation might well be expected to affect 
susceptibility to sparfloxacin more than to other quino- 
lones. However, this suggestion is just speculation and 
requires confirmation. 
To answer the other points . . . to use the most 
active quinolone (sparfloxacin) at full dosage would 
certainly seem to carry the greatest likelihood of a 
successful outcome. Ofloxacin was used at a rather low 
dose in this case, in my opinion. The problem ofwhich 
quinolone to use to test the susceptibility to the class 
of quinolones is a thorny issue. The Working Party 
of the British Society for Antimicrobial Chemo- 
therapy (4) suggested that the least active member of a 
group of similar agents should be chosen to represent 
the group, because “false sensitivity” rather than “false 
resistance” is the lesser of two evils in susceptibility 
reporting. 
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